Company intelligence / Profile preview
Zion Pharma
Shanghai, Shanghai, Chinazionpharma.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Zion Pharma develops small-molecule drugs for oncology, focusing on brain-permeable compounds. Its lead asset, ZN-A‑1041—a blood-brain barrier penetrant oral HER2 tyrosine kinase inhibitor—was licensed globally to Roche in a deal worth up to $680M. The drug aims to treat or prevent brain metastases in patients with HER2-positive metastatic breast cancer and had reached Phase 1 trials before the partnership. Additional programs include an ATM inhibitor for advanced solid tumors.[1][2][3]
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Roche – global rights agreement for ZN-A‑1041 ($70M upfront, up to $610M milestones plus royalties); Roche leads further development and commercialization.[6]
Beyond the preview
Go deeper on Zion Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zion Pharma.